Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability
By Prakash Khadka, J. Ro, Hyeongmin Kim, Iksoo Kim, Jeong Tae Kim, Hyun-Il Kim, Jae Min Cho, Gyiae Yun, Jaehwi Lee. 2014
985 citations recorded by the source corpus.
Abstract Pharmaceutical particle technology is employed to improve poor aqueous solubility of drug compounds that limits in vivo bioavailability owing to their low dissolution rate in the gastrointestinal fluids following oral administration. The particle technology involves several approaches from the conventional size reduction processes to the newer, novel particle technologies that modify the solubility properties of the drugs and produce solid, powdered form of the drugs that are readily soluble in water and can be easily formulated into various dosage forms. This review highlights the solid particle technologies available for improving solubility, dissolution and bioavailability of drugs with poor aqueous solubility.
Subfields: Pharmaceutical Science, Pharmacology
View Paper: https://www.semanticscholar.org/paper/b29070c4ec014a53c59f62ffcd5dd88912a57505
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Hanan A Henidi
- Azeez Yusuf
- Awatif R. Z. Almotairy
- A. Grumezescu
- E. Andronescu
- A. Ficai
- Oana Gherasim
- Alexandra-Cristina Burdușel
Citations in the corpus
- Nanoparticles as Drug Delivery Systems: A Review of the Implication of Nanoparticles’ Physicochemical Properties on Responses in Biological Systems (2023, background): “It is currently hypothesised that most conventional drugs have poor bioavailability and aqueous solubility limiting their absorption and retention within biological systems [31], as such significant efforts are being made to improve the efficiency of many traditional/conventional drugs.”
- Biomedical Applications of Silver Nanoparticles: An Up-to-Date Overview (2018, background): “Moreover, such a particular drug-delivery [90] platform should not only provide suitable and adjustable drug loading and releasing profiles, but should also enable [70] maximal therapeutic efficiency at concentrations below that of the sole biosubstance with side-effect minimization [91,92].”